April 17 OncoMed Pharmaceuticals Inc said on Monday its experimental drug failed a mid-stage study for the treatment of lung cancer.
The trial was testing the combination of Oncomed's tarextumab and chemotherapy, compared with chemotherapy and a placebo. The main goal was to slow the progression of the disease.
Last week, the company said it would discontinue a trial testing its experimental drug, demcizumab, as an initial treatment for advanced pancreatic cancer. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Anil D'Silva)
ChargePoint secures $43 million in funding led by Siemens
SAN FRANCISCO, June 28 Electric vehicle charging station maker ChargePoint Inc said on Wednesday it had secured $43 million in financing led by German engineering group Siemens AG, bringing to a close the U.S. company's latest funding round at $125 million.
UK car output falls 10 pct in May ahead of new models
LONDON, June 29 British car production fell 9.7 percent in May as some major manufacturers reached the end of older product lines and prepared to begin building newer models, an industry body said on Thursday.